Open Label Phase II Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Growth disorders
- Focus Therapeutic Use
- Acronyms EPASOS
- 24 Feb 2016 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 22 Feb 2016 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov record.
- 08 Oct 2015 New trial record